Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.

Patricia Martin-RomanoEduardo CastanonSamy AmmariStéphane ChampiatAntoine HollebecqueSophie Postel-VinayCapucine BaldiniAndrea VargaJean Marie MichotPerrine VuagnatAurélien MarabelleJean-Charles SoriaCharles FertéChristophe Massard

Published in: Cancer medicine (2020)

A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune-related response evaluations may require further attention.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
working memory
patient reported
clinical evaluation